Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Elicio Therapeutics, Inc.

vedantra.com
Filed: Mar 16, 2026BOSTON, MACIK: 0001601485Biotechnology
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Elicio Therapeutics secured a $100 million At-the-Market (ATM) offering agreement with three sales agents, allowing the company to issue common stock flexibly based on market conditions to fund immunotherapy development.

Key Takeaways

Company entered into an ATM agreement with B. Riley Securities, JonesTrading Institutional Services, and Ladenburg Thalmann & Co. for up to $100 million in common stock sales

The offering provides capital flexibility, allowing Elicio to raise funds opportunistically aligned with market conditions rather than in a single transaction

2 more takeaways

Related Filings (1)

1 more filing from Elicio Therapeutics, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateMar 16, 2026
Item1.01
CategoryMaterial Agreement
CIK0001601485
Accession #0001601485
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offeringmaterial agreement

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings